BACKGROUND: The two main tumors treated with Mohs micrographic surgery (MMS) are basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). There are no studies analyzing whether MMS is different when treating these two types of tumors. OBJECTIVE: We aim to compare the characteristics of the patients, the tumors, and MMS, and first-year follow-up of MMS in BCC and SCC. METHODS: REGESMOHS is a prospective cohort study of patients treated with MMS. The participating centers are 19 Spanish hospitals where at least one MMS is performed per week. Data on characteristics of the patients, tumors, and surgery were recorded. The follow-up was done with two visits: the first visit within 1 month after surgery and the second one within the first year. RESULTS: From July 2013 to April 2017, a total of 2,669 patients who underwent MMS were included in the registry. Of them, 2,448 (93%) were diagnosed with BCC, and 181 (7%) were diagnosed with SCC. Patients with SCC were older than those with BCC (median age 73 years vs. 68 years) and presented immunosuppression more frequently. The tumor size was significantly larger in the SCC group. Regarding surgery, deeper invasion was more frequent in SCC, resulting in larger defects. Despite this, SCC did not require more stages to get clear margins or more time in the operating room. Incomplete Mohs was more frequent in the SCC group (6%) than in the BCC group (2%). The incidence of perioperative complications was higher when treating SCC. There were more relapses in the first-year follow-up in the SCC group. CONCLUSION: There are significant differences when comparing MMS in BCC and SCC. Knowledge of these differences can help to prepare the patient and plan the surgery, optimizing results.
BACKGROUND: The two main tumors treated with Mohs micrographic surgery (MMS) are basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). There are no studies analyzing whether MMS is different when treating these two types of tumors. OBJECTIVE: We aim to compare the characteristics of the patients, the tumors, and MMS, and first-year follow-up of MMS in BCC and SCC. METHODS: REGESMOHS is a prospective cohort study of patients treated with MMS. The participating centers are 19 Spanish hospitals where at least one MMS is performed per week. Data on characteristics of the patients, tumors, and surgery were recorded. The follow-up was done with two visits: the first visit within 1 month after surgery and the second one within the first year. RESULTS: From July 2013 to April 2017, a total of 2,669 patients who underwent MMS were included in the registry. Of them, 2,448 (93%) were diagnosed with BCC, and 181 (7%) were diagnosed with SCC. Patients with SCC were older than those with BCC (median age 73 years vs. 68 years) and presented immunosuppression more frequently. The tumor size was significantly larger in the SCC group. Regarding surgery, deeper invasion was more frequent in SCC, resulting in larger defects. Despite this, SCC did not require more stages to get clear margins or more time in the operating room. Incomplete Mohs was more frequent in the SCC group (6%) than in the BCC group (2%). The incidence of perioperative complications was higher when treating SCC. There were more relapses in the first-year follow-up in the SCC group. CONCLUSION: There are significant differences when comparing MMS in BCC and SCC. Knowledge of these differences can help to prepare the patient and plan the surgery, optimizing results.
Authors: Alejandra Tomás-Velázquez; Onofre Sanmartin-Jiménez; Joan R Garcés; Manuel A Rodríguez-Prieto; Verónica Ruiz-Salas; Esther De Eusebio-Murillo; Román Miñano-Medrano; Begoña Escutia-Muñoz; Ángeles Flórez-Menéndez; Juan L Artola-Igarza; Alberto Alfaro-Rubio; Pilar Gil; Yolanda Delgado-Jiménez; Julia M Sanchez-Schmidt; Irati Allende-Markixana; María L Alonso-Pacheco; Beatriz García-Bracamonte; Pablo De la Cueva-Dobao; Raquel Navarro-Tejedor; Cristina Ciudad-Blanco; Lucía Carnero-González; Hugo Vázquez-Veiga; Natividad Cano-Martínez; Eva Vilarrasa-Rull; Pedro Sanchez-Sambucety; José L López-Estebaranz; Rafael Botella-Estrada; Beatriz Gonzalez-Sixto; Antonio Martorell-Calatayud; Victoriano Morales-Gordillo; Agustí Toll-Abelló; Izascun Ocerin-Guerra; Matías Mayor-Arenal; Ricardo Suárez-Fernández; Laura Sainz-Gaspar; Miguel A Descalzo; Ignacio García-Doval; Pedro Redondo Journal: Acta Derm Venereol Date: 2021-11-24 Impact factor: 3.875